|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New Jersey Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New JerseyLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Aerie Pharmaceuticals, Inc.
| | | Phone: | (908) 685-0069 | Fax: | (908) 685-0087 | Year Established: | 2005 | Ticker: | AERI | Exchange: | NASDAQ | Main Contact: | Vicente Anido, Jr., Ph.D., Chairman & CEO | | Other Contacts: | Concetta Perro, Commercial Counsel John LaRocca, General Counsel Julia Williams, Director of Medical Affairs Norbert Lowe, Regional Sales Director Richard (Rick) A. Halprin, Director of Professional Affairs Judith J. Robertson, CCO Deanne Melloy, VP, Marketing Thomas Mitro, President & COO Richard J. Rubino, CFO Craig R. Skenes, VP, Business Development Casey C. Kopczynski, Ph.D., CSO & Co-Founder Brian Levy, O.D., M.Sc., CMO Theresa Heah, M.D., M.B.A., VP, Clinical Research & Medical Affairs John Maltman, Ph.D., VP, Medical Affairs Robert Finan, Director of Finance Thomas A. Shepard, VP, Implant Manufacturing
| | Company Description | Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie is currently conducting a Phase 3 registration trial in the United States named Rocket 2, where the primary efficacy endpoint is to demonstrate non-inferiority of IOP lowering for RhopressaTM compared to timolol, along with a Phase 3 registration safety-only trial, named Rocket 3, in Canada. Aerie recently completed its initial Phase 3 registration trial, named Rocket 1, the three-month efficacy results of which were initially reported in April 2015, and expects to commence a fourth Phase 3 registration trial, named Rocket 4, in the third quarter of 2015. Aerie also completed in 2014 a Phase 2b clinical trial in which RoclatanTM met the primary efficacy endpoint, demonstrating the statistical superiority of RoclatanTM to each of its components, and plans to commence the first Phase 3 registration trial for RoclatanTM, named Mercury 1, in the third quarter of 2015. | |
|
|
|